Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026)

Xeris Biopharma Holdings has reported Cash & Equivalents for 7 years, with the latest figure at $111.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 91.22% year-over-year to $111.8 million; the trailing twelve-month figure through Mar 2026 stood at $111.8 million (up 91.22% YoY), and the FY2025 full-year result was $111.0 million, up 55.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $111.8 million, up from $111.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $122.0 million in Q4 2022, with the low at $46.1 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $76.4 million across 5 years, with a median of $67.4 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 51.57% — and 2026, when it soared 91.22%.
• Xeris Biopharma Holdings' Cash & Equivalents stood at $122.0 million in 2022, then slumped by 44.7% to $67.4 million in 2023, then increased by 6.19% to $71.6 million in 2024, then surged by 55.04% to $111.0 million in 2025, then increased by 0.64% to $111.8 million in 2026.
• The last three Cash & Equivalents figures came in at $111.8 million (Q1 2026), $111.0 million (Q4 2025), and $91.6 million (Q3 2025), per Business Quant data.